Literature DB >> 25060015

Impact of delay to reperfusion on reperfusion success, infarct size, and clinical outcomes in patients with ST-segment elevation myocardial infarction: the INFUSE-AMI Trial (INFUSE-Anterior Myocardial Infarction).

Alejandra Guerchicoff1, Sorin J Brener2, Akiko Maehara1, Bernhard Witzenbichler3, Martin Fahy1, Ke Xu1, Bernard J Gersh4, Roxana Mehran5, C Michael Gibson6, Gregg W Stone7.   

Abstract

OBJECTIVES: Our aim was to study the impact of delay from symptom onset to first coronary device on infarct size and clinical outcomes at 30 days and 1 year in patients with ST-segment elevation myocardial infarction (STEMI) treated with primary percutaneous coronary intervention.
BACKGROUND: Longer delay from symptom onset to reperfusion has been linked to increased mortality and worse clinical outcome. The mechanisms underpinning this association are not entirely clear.
METHODS: The INFUSE-AMI trial (INFUSE-Anterior Myocardial Infarction) randomized patients with anterior STEMI undergoing primary percutaneous coronary intervention with bivalirudin anticoagulation within 5 h of symptom onset to intralesion (IL) bolus abciximab versus no abciximab and to thrombus aspiration versus no aspiration. The primary endpoint was contrast magnetic resonance infarct size (IS) (percentage of left ventricular mass) at 30 days. Time to reperfusion was classified as <3 versus ≥3 h.
RESULTS: There were 280 patients (62%) with <3-h delay and 170 patients (38%) with ≥3-h delay. Patients with longer delay were significantly older, more often women, and diabetic. Earlier reperfusion was not associated with higher rates of final Thrombolysis In Myocardial Infarction flow grade 3 or myocardial blush grade 2/3, but was an independent predictor of smaller IS (p = 0.02 by multivariable linear regression). Mortality at 1 year was reduced in patients with shorter delay to reperfusion (4.0% vs. 9.2%, p = 0.02).
CONCLUSIONS: In patients with large anterior myocardial infarction undergoing relatively early reperfusion, longer delays to reperfusion were associated with larger IS and 1-year mortality, but not with reduced reperfusion success. (The INFUSE - Anterior Myocardial Infarction [AMI] Study; NCT00976521).
Copyright © 2014 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  STEMI; infarct size; ischemic time; myocardial blush grade; outcome

Mesh:

Substances:

Year:  2014        PMID: 25060015     DOI: 10.1016/j.jcin.2014.01.166

Source DB:  PubMed          Journal:  JACC Cardiovasc Interv        ISSN: 1936-8798            Impact factor:   11.195


  18 in total

Review 1.  Platelet GP IIb-IIIa Receptor Antagonists in Primary Angioplasty: Back to the Future.

Authors:  Giuseppe De Luca; Stefano Savonitto; Arnoud W J van't Hof; Harry Suryapranata
Journal:  Drugs       Date:  2015-07       Impact factor: 9.546

2.  Aspiration thrombectomy in 2015: a TOTAL defeat?

Authors:  Marco De Carlo; Marco Angelillis
Journal:  J Thorac Dis       Date:  2016-01       Impact factor: 2.895

3.  Prehospital Delay in Older Adults with Acute Myocardial Infarction: The ComprehenSIVe Evaluation of Risk Factors in Older Patients with Acute Myocardial Infarction Study.

Authors:  Gregory M Ouellet; Mary Geda; Terrence E Murphy; Sui Tsang; Mary E Tinetti; Sarwat I Chaudhry
Journal:  J Am Geriatr Soc       Date:  2017-10-18       Impact factor: 5.562

4.  Real-world, feasibility study to investigate the use of a multidisciplinary app (Pulsara) to improve prehospital communication and timelines for acute stroke/STEMI care.

Authors:  Chris F Bladin; Kathleen L Bagot; Michelle Vu; Joosup Kim; Stephen Bernard; Karen Smith; Grant Hocking; Tessa Coupland; Debra Pearce; Diane Badcock; Marc Budge; Voltaire Nadurata; Wayne Pearce; Howard Hall; Ben Kelly; Angie Spencer; Pauline Chapman; Ernesto Oqueli; Ramesh Sahathevan; Thomas Kraemer; Casey Hair; Dion Stub; Dominique A Cadilhac
Journal:  BMJ Open       Date:  2022-07-18       Impact factor: 3.006

5.  Impact of generalized anxiety disorder (GAD) on prehospital delay of acute myocardial infarction patients. Findings from the multicenter MEDEA study.

Authors:  X Y Fang; D Spieler; L Albarqouni; J Ronel; K-H Ladwig
Journal:  Clin Res Cardiol       Date:  2018-01-30       Impact factor: 5.460

6.  Culprit plaque characteristics in women vs men with a first ST-segment elevation myocardial infarction: In vivo optical coherence tomography insights.

Authors:  Rong Sun; Liping Sun; Yandong Fu; Huimin Liu; Maoen Xu; Xuefeng Ren; Huai Yu; Hui Dong; Yang Liu; Yinchun Zhu; Jinwei Tian; Bo Yu
Journal:  Clin Cardiol       Date:  2017-12-16       Impact factor: 2.882

7.  Impact of COVID-19 outbreak on patients with ST-segment elevation myocardial ınfarction (STEMI) in Turkey: results from TURSER study (TURKISH St-segment elevation myocardial ınfarction registry).

Authors:  Tuncay Kiris; Eyüp Avci; Tuba Ekin; Didar Elif Akgün; Mücahit Tiryaki; Arafat Yidirim; Kutluhan Hazir; Bektaş Murat; Mehtap Yeni; Rojhad Altindag; Sefa Gül; Baran Arik; Tuncay Güzel; Selda Murat; Ahmet Oz; Mustafa Karabacak; Zihni Aktas; Tarik Yildirim; Baris Kilicaslan; Asim Oktay Ergene
Journal:  J Thromb Thrombolysis       Date:  2021-05-29       Impact factor: 5.221

8.  Very late presentation in ST elevation myocardial infarction: Predictors and long-term mortality.

Authors:  Patrick W McNair; Kenneth C Bilchick; Ellen C Keeley
Journal:  Int J Cardiol Heart Vasc       Date:  2019-02-20

9.  Duration of Inducible Ventricular Tachycardia Early After ST-Segment-Elevation Myocardial Infarction and Its Impact on Mortality and Ventricular Tachycardia Recurrence.

Authors:  Tejas Deshmukh; Sarah Zaman; Arun Narayan; Pramesh Kovoor
Journal:  J Am Heart Assoc       Date:  2020-06-23       Impact factor: 5.501

10.  A novel fibroblast growth factor-1 ligand with reduced heparin binding protects the heart against ischemia-reperfusion injury in the presence of heparin co-administration.

Authors:  Chahua Huang; Yang Liu; Andrew Beenken; Lin Jiang; Xiang Gao; Zhifeng Huang; Anna Hsu; Garrett J Gross; Yi-Gang Wang; Moosa Mohammadi; Jo El J Schultz
Journal:  Cardiovasc Res       Date:  2017-11-01       Impact factor: 10.787

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.